首页> 外文期刊>Experimental and clinical transplantation >Validation of Donor-Specific Tolerance of Intestinal Transplant by a Secondary Heart Transplantation Model
【24h】

Validation of Donor-Specific Tolerance of Intestinal Transplant by a Secondary Heart Transplantation Model

机译:二次心脏移植模型对供体特异性肠移植耐受性的验证

获取原文
           

摘要

Objectives: It is well accepted that survival after a second organ transplant without immunosuppressive agents indicates tolerance for the first transplant. To validate donor-specific tolerance, we established arat model with a secondary heart transplant after intestinal transplant, which has so far not been described in the literature. Materials and Methods: We transplanted intestine from Fischer F344 rats to Lewis rats orthotopically. Lewis rats received tacrolimus pretreatment before trans-plant and a 14-day course of rapamycin 1 month after transplant. At 120 days after primary intestinal transplant, hearts from 6 F344 rats (group A) or 6 Brown Norway rats (group B) were transplanted to Lewis rats that had survived intestinal transplant and without additional immunosuppressive agents. We analyzed survival data, histologic changes, cells positive for the ED1 macrophage marker in trans-planted hearts, and 3 lymphocyte levels in both groups. Results: Thirty days after secondary heart transplant, group A hearts were continuously beating; however, group B hearts stopped beating at around 10 days after transplant (8.5 ± 1.5 d; P .05). Fluorescence-activated cell sorting showed that CD4/CD25-positive regulatory T cell, CTLA4/CD4/CD25-positive regulatory T cell, and Natural killer T-cell levels were significantly higher level in group A versus B ( P < .05). Conclusions: The donor-specific tolerance that we observed was possibly a state of “clinical tolerance” rather than “immunologic tolerance.” Our rat model is a feasible and reliable model to study donor-specific tolerance. The higher levels of lymphocytic T cells shown in intestinal transplant recipients were associated with longer allograft survival, possibly contributing to donor-specific tolerance.
机译:目的:公认的是,在没有免疫抑制剂的情况下进行第二次器官移植后的存活率表明对第一次移植的耐受性。为了验证供体特异性耐受性,我们在肠道移植后通过二次心脏移植建立了大鼠模型,该文献迄今尚未有描述。材料和方法:我们将原位Fischer F344大鼠的肠移植到Lewis大鼠。 Lewis大鼠在移植前接受他克莫司预处理,移植后1个月接受雷帕霉素14天疗程。在初次肠移植后120天,将6只F344大鼠(A组)或6只Brown Norway大鼠(B组)的心脏移植到在肠道移植中存活且没有其他免疫抑制剂的Lewis大鼠。我们分析了存活数据,组织学变化,移植心脏中ED1巨噬细胞标记阳性的细胞以及两组的3种淋巴细胞水平。结果:二次心脏移植后第30天,A组心脏持续跳动。然而,B组心脏在移植后约10天(8.5±1.5 d; P .05)停止跳动。荧光激活细胞分选显示,A组的CD4 / CD25阳性调节性T细胞,CTLA4 / CD4 / CD25阳性调节性T细胞和自然杀伤性T细胞水平明显高于B组(P <.05)。结论:我们观察到的供体特异性耐受可能是“临床耐受”状态,而不是“免疫耐受”状态。我们的大鼠模型是研究供体特异性耐受性的可行且可靠的模型。在肠移植受者中显示出更高水平的淋巴细胞T细胞与同种异体移植物的存活时间更长有关,可能有助于供体特异性耐受。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号